Expression of vascular endothelial growth factor receptors in human prostate cancer. 1999

F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
Department of Surgery, University of Connecticut Health Center, Farmington 06030-3105, USA.

OBJECTIVE We recently reported the expression and cytokine regulation of vascular endothelial growth factor (VEGF) in human prostate cancer (PCa). VEGF exerts its angiogenic and pro-tumorigenic properties by way of two high affinity receptors, fms-like tyrosine kinase 1 (FLT-1) and fetal liver kinase 1 (FLK-1). We hypothesized that these receptors are expressed and control VEGF functions in the PCa microenvironment. Herein, we evaluate the expression of these receptors in ex vivo PCa tissue, benign prostatic hypertrophy (BPH) tissue, and cultured PCa cell lines. METHODS Ex vivo PCa specimens were obtained from patients undergoing radical retropubic prostatectomy. Specimens were selected to contain both PCa and BPH tissue (n = 15). Immunohistochemical analysis using antihuman FLT-1 and FLK-1 was performed and specimens were analyzed to characterize the expression and distribution of both receptors. Immunocytochemical analysis for FLT-1 and FLK-1 was also performed on cultured PCa cell lines (DU-145 and LNCaP). RESULTS PCa cells expressed the VEGF receptor FLT-1 in 100% of specimens evaluated. Expression of FLK-1 was variable and related to tumor grade; high-grade tumors displayed little or no FLK-1 expression. Vascular endothelial cells (VECs) within areas of PCa consistently expressed both FLT-1 and FLK-1 receptors. FLT-1 and FLK-1 were both expressed in BPH tissue. FLT-1 was expressed in the glandular epithelial cells in BPH, but in most cases FLK-1 was localized specifically to the basal cell layer of hypertrophic glands. FLT-1, but not FLK-1, was expressed by the DU-145 and LNCaP cell lines. CONCLUSIONS Although they are differentially expressed, both FLT-1 and FLK-1 are present in PCa and BPH. Expression of receptors on VECs of tumor vessels supports the well-established role of VEGF in paracrine stimulation of VECs in the tumor microenvironment. The expression of FLT-1 and FLK-1 on tumor cells themselves suggests a potential autocrine function for VEGF (such as regulating tumor cell proliferation). These findings imply that a novel dual role may exist for VEGF, such that it is involved in tumor cell activation (autocrine), in addition to paracrine actions whereby it regulates endothelial cell functions and subsequent neovascular development.

UI MeSH Term Description Entries
D008297 Male Males
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D017978 Receptors, Growth Factor Cell surface receptors that bind growth or trophic factors with high affinity, triggering intracellular responses which influence the growth, differentiation, or survival of cells. Growth Factor Receptor,Growth Factor Receptors,Trophic Factor Receptors,Receptors, Growth Factors,Receptors, Trophic Factor,Trophic Factor Receptor,Factor Receptor, Growth,Factor Receptor, Trophic,Growth Factors Receptors,Receptor, Growth Factor,Receptor, Trophic Factor
D020794 Receptor Protein-Tyrosine Kinases A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity. PTK Receptor,Receptors, Protein-Tyrosine Kinase,Tyrosine Kinase Linked Receptor,Tyrosine Kinase Linked Receptors,Tyrosine Kinase Receptor,Tyrosine Kinase Receptors,PTK Receptors,Protein-Tyrosine Kinase Receptor,Receptor Protein-Tyrosine Kinase,Kinase Receptor, Tyrosine,Kinase, Receptor Protein-Tyrosine,Kinases, Receptor Protein-Tyrosine,Protein-Tyrosine Kinase Receptors,Protein-Tyrosine Kinase, Receptor,Protein-Tyrosine Kinases, Receptor,Receptor Protein Tyrosine Kinase,Receptor Protein Tyrosine Kinases,Receptor, PTK,Receptor, Protein-Tyrosine Kinase,Receptor, Tyrosine Kinase,Receptors, PTK,Receptors, Protein Tyrosine Kinase
D040262 Receptors, Vascular Endothelial Growth Factor A family of closely related RECEPTOR PROTEIN-TYROSINE KINASES that bind vascular endothelial growth factors. They share a cluster of seven extracellular IG-LIKE DOMAINS which are important for ligand binding. They are highly expressed in vascular endothelial cells and are critical for the physiological and pathological growth, development and maintenance of blood and lymphatic vessels. Endothelial Growth Factor Receptor,Receptor, Endothelial Growth Factors,Receptor, Vascular Endothelial Cell Growth Factor,Receptor, Vascular Permeability Factor,VEGF Receptor,VEGF Receptors,VPF Receptor,Vascular Endothelial Cell Growth Factor Receptor,Vascular Endothelial Growth Factor Receptor,Vascular Permeability Factor Receptor,Receptors, VEGF

Related Publications

F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
July 2000, Urology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
January 1995, Human pathology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
January 2001, Journal of andrology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
February 2004, The Canadian journal of urology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
October 2000, Analytical and quantitative cytology and histology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
July 2007, Oncology reports,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
January 2014, Biochemical pharmacology,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
August 2001, British journal of cancer,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
June 2015, Endocrine-related cancer,
F A Ferrer, and L J Miller, and R Lindquist, and P Kowalczyk, and V P Laudone, and P C Albertsen, and D L Kreutzer
August 2006, Urology,
Copied contents to your clipboard!